

Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide Mouse Monoclonal Antibody [Clone 1G12] Catalog # AH11314

Specification

Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide - Product Information

Application Primary Accession Other Accession Reactivity Host Clonality Isotype Calculated MW IHC, IF, FC <u>P51654</u> <u>2719, 644108</u> Human Mouse Monoclonal Mouse / IgG1, kappa 67kDa KDa

Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide - Additional Information

Gene ID 2719

Other Names Glypican-3, GTR2-2, Intestinal protein OCI-5, MXR7, Secreted glypican-3, GPC3, OCI5

Application Note IHC~~1:100~500<br \>IF~~1:50~200<br \>FC~~1:10~50

Storage Store at 2 to 8°C.Antibody is stable for 24 months.

Precautions Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide -Protein Information

Name GPC3

Synonyms OCI5

Function

Cell surface proteoglycan (PubMed:14610063). Negatively regulates the hedgehog signaling pathway when attached via the GPI- anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins (By similarity). Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation (By



similarity). Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands (PubMed:16227623, PubMed:24496449). Positively regulates the non-canonical Wnt signaling pathway (By similarity). Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression (By similarity). Inhibits the dipeptidyl peptidase activity of DPP4 (PubMed:17549790). Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4 (By similarity). Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis (By similarity). Required for coronary vascular development (By similarity). Plays a role in regulating cell movements during gastrulation (By similarity).

Cellular Location

Cell membrane; Lipid-anchor, GPI-anchor {ECO:0000250|UniProtKB:P13265}; Extracellular side {ECO:0000250|UniProtKB:P13265}

Tissue Location

Detected in placenta (at protein level) (PubMed:32337544). Highly expressed in lung, liver and kidney

Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide -Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide -Images



Formalin-fixed, paraffin-embedded human Hepatocellular Carcinoma stained with Glypican-3 Monoclonal Antibody (1G12)



Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide -Background

Recognizes a protein, which is identified as HGAL. It contains a putative PDZ-interacting domain, an immunoreceptor tyrosine-based activation motif (ITAM), and two putative SH2 binding sites. In B cells, its expression is specifically induced by interleukin-4.Ā HGAL is specifically expressed in germinal center B-cells, but is absent in mantle and marginal zone B-cells and in the inter-follicular and para-cortical regions in normal tonsils and lymph nodes. Its high degree of specificity for germinal center B-cells makes anti-HGAL an ideal marker for the detection of germinal center -derived B-cell lymphomas. HGAL expression has been used to help elucidate nodal marginal zone lymphoma (NMZL) from cases of diffuse follicle center lymphoma. Additionally, HGAL expression was shown to correlate with survival in patients with diffuse large B-cell lymphoma (DLBCL).

Glypican-3 (GPC3) (Hepatocellular Carcinoma Marker) Antibody - With BSA and Azide -References

Yan, B., et al. 2011. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann. Diagn. Pathol. 15: 162-169